We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Retinitis Pigmentosa
- RP: regenerative and neuroprotective strategies
- Repair of the diseased retina
- Retinal transplantation: intracerebral retinal grafts
- Retinal transplants are functional
- Can neural stem cells replace dead retina cells?
- Transplanted neural stem cells
- Hippocampal stem cells grafted to rat RP model
- Transplantation in early embryonic-like host
- Illustration of retinal morphology
- Cell therapy strategies
- Retinal development
- Retinal stem cells grafted to subretinal space
- Cells develop into rhodopsin, photoreceptors
- Our approach: cell culture
- Our approach: transplantation
- Key objectives
- Human fetal retina
- Human fetal retina:18 wk gestational age
- Phenotype of hRPCs across passages/donations
- Gene expression analysis across donations
- Cell expansion
- Cell isolation and banking
- Differentiation on PCL
- Differentiation: qPCR
- Stemness: qPCR
- Photoreceptor markers expression
- Photoreceptor-like response to GluR agonists
- In vivo studies
- Subretinal injections in Rho -/- mice
- hRPC form rods in Rho -/- mice
- Efficacy study in RCS dystrophic rats
- Pig RPCs are similar to human RPCs
- Allogeneic transplantation in pigs
- pRPCs differentiate into rods
- Immune suppression is not required
- Allogeneic transplantation: survival & dosage (1)
- Graft of subretinal space RPCs
- Allogeneic transplantation: survival & dosage (2)
- Retinal progenitor cells
- Clinical development
- Thank you
Topics Covered
- Retinitis pigmentosa
- Stem cell therapy
- Intracerebral retinal transplantation
- Transplantation of neural stem cells
- Retinal progenitor cell transplantation
- Characterization of hRPCs
- In vivo studies
- Allogeneic transplantation
- Clinical development
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Young, M. (2016, December 28). Translating retinal stem cells [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 5, 2024, from https://doi.org/10.69645/IXZD5208.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Michael Young has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: Macular Degeneration
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Michael Young
from the Schepens Eye Research Institute,
Massachusetts Eye and Ear,
Harvard Stem Cell Institute.
I'm in the Department of Ophthalmology
at Harvard Medical School,
talking to you today
about translating retinal stem cells.
0:13
So the disease that we focus on
in my laboratory
for treating with stem cells
is retinitis pigmentosa.
The retinitis pigmentosa
are a group of hereditary diseases
that cause retinal degeneration
and there are a lot of different diseases,
there are actually hundreds
of different mutations
that can lead to retinitis pigmentosa,
but the common feature is that
rod photoreceptors typically die first.
And again,
there is no effective treatment at present
for this disease.
0:38
What is new in this field
is that there are a host of new regenerative
and neuroprotective strategies
available to treat retinitis pigmentosa.
So these include gene therapy,
neuroprotection with growth factors,
implants such as prosthetic chips
that are being devised
to integrate with the visual system
in a variety of different ways,
a brand new field called optogenetics
in which non-photosensitive cells
are induced to become photosensitive
through gene transfer technology;
And what I'm going to talk to you today
about, principally, is cell replacement.
I'm really talking mostly
about replacing rods and cones.
1:13
So the diseased retina has been
thought of as a structure
that can be repaired for many years,
but most of these attempts have failed.
But these retinal transplants
we'll call them, have been performed
without the use of stem cells,
so with embryonic tissue, fetal tissue,
even adult tissue
but not expanded stem cells;
And these grafts have failed principally
because they did not connect to the host.
So what's new is that stem cells
can overcome this barrier
and integrate with the host.
But this brings up a new challenge
and that is to harness
the plasticity of these cells,
and that means differentiation -
getting these cells to become
the type of cells
that we really want them to become.
And in the case of the work
I'm talking about today,
that really is rod photoreceptor.